RESULTS Act
Summary
The RESULTS Act (S.2761) proposes shifting Medicare Part B lab test payment rate data collection from CMS to an independent nonprofit, targeting the key revenue risk for $LH and $DGX under PAMA. The bill is early-stage (referred to committee) and faces a multi-year path, but its mechanism directly addresses a structural headwind that has driven ~10% cumulative Medicare rate cuts since 2018. Real market data shows a 5-day selloff in both tickers — $LH dropped from $270.68 to $263.99 and $DGX from $195.02 to $195.64 — creating an entry point for investors betting on legislative momentum for reimbursement stability.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.RESULTS Act targets the primary structural revenue risk for $LH and $DGX — PAMA-driven Medicare Part B rate cuts by reforming data collection methodology.
- 2.The bill is early-stage (referred to committee) with bipartisan sponsorship, but actual passage likely in late 2026 at the earliest; no immediate revenue impact.
- 3.Real market data shows $LH and $DGX recovered sharply on April 30 from a 5-day selloff, suggesting the market is pricing in increased probability of reimbursement stability.
- 4.No federal spending is authorized — this is a data collection reform that changes how rates are set, not the total pool of Medicare lab spending.
Market Implications
The 5-day selloff in $LH and $DGX created a clear entry opportunity for investors betting on legislative momentum for PAMA reform. $LH closed at $263.99 on April 30, near the middle of its 52-week range ($235.81-$293.72). $DGX closed at $195.64, also near the middle of its range ($164.65-$213.50). The sharp April 30 reversal (+2.66% for $LH, +3.33% for $DGX) indicates the market is reassessing PAMA risk. Investors should watch three milestones: (1) committee markup in Senate Finance (look for a hearing date), (2) House companion bill advancement through Energy and Commerce, and (3) CBO scoring, which may clarify whether the bill is budget-neutral (likely) or has a small positive impact on Medicare spending. The key risk is that the bill stalls — early-stage healthcare payment reform bills have historically low passage rates (~15-20% for introduced bills becoming law). Position sizing should account for this legislative uncertainty.
Full Analysis
What happened: On September 10, 2025, Senator Tillis (R-NC) introduced S.2761, the RESULTS Act (Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025). The bill was read twice and referred to the Senate Committee on Finance. A companion bill, H.R.5269, has been introduced in the House and referred to Energy and Commerce and Ways and Means. The bill is in early legislative stage — single-digit cosponsors and no committee markup yet. However, the bipartisan sponsorship (Tillis-R, Warnock-D) and the presence of a House companion signal committee engagement. The money trail: This bill does not authorize or appropriate any federal spending. It is a data collection reform — it changes how Medicare Part B lab test payment rates are calculated, not the total amount spent. The mechanism replaces CMS's current PAMA data collection (which uses a mandatory reporting system of lab data that CMS admits has statistical shortcomings) with data from a qualified independent nonprofit comprehensive claims database. This is significant because PAMA's flawed data collection has led to CMS applying weights that underestimate private payor rates, resulting in ~10% cumulative cuts to the Clinical Laboratory Fee Schedule since 2018. Structural winners and losers: The direct beneficiaries are the two largest independent lab companies — Labcorp ($LH) and Quest Diagnostics ($DGX). Both derive 10-12% of their revenue from Medicare Part B lab testing. Hospital outreach labs and smaller independent labs also benefit, but they are not publicly traded pure-plays. The bill is neutral for CMS and the Medicare Trust Fund (no spending changes). Real market data: Over the past 5 trading days (April 23-30, 2026), $LH fell from $264.92 to $263.99 (-0.35%), with a low of $257.14 on April 29. $DGX fell from $199.53 to $195.64 (-1.95%), with a low of $189.32 on April 29. Both recovered sharply on April 30 — $LH gained $6.85 (+2.66%) and $DGX gained $6.31 (+3.33%) — suggesting the selloff may have been overdone and the market is re-evaluating the reimbursement risk. The 7-day change for $LH is +0.07% and for $DGX is -0.33%, indicating the 5-day selloff was largely reversed on the last day. Timeline: The bill faces significant legislative steps — committee markup (Finance Senate, Energy and Commerce/Ways and Means House), floor votes in both chambers, conference committee if differences exist, and presidential signature. Given the 2026 midterm elections and the bill's data collection start date of January 1, 2027, the earliest realistic passage is late 2026. The bipartisan sponsorship and narrow technical scope increase the bill's odds relative to most early-stage legislation.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Replaces CMS-administered PAMA data collection with an independent nonprofit comprehensive claims database for setting Medicare Part B lab test payment rates, starting with data collection periods on or after January 1, 2027.
Who must act
Clinical diagnostic laboratories that bill Medicare Part B, including Labcorp.
What happens
Shifts the data source used to calculate private payor-based fee schedule rates from a CMS-mandated reporting system (which has led to steep, unpredictable rate cuts) to a qualified independent nonprofit database. This reduces the risk of CMS-administrative errors and data-weighting imbalances that have caused 10-15% cumulative PAMA cuts since 2018.
Stock impact
LH's largest revenue segment is Labcorp Diagnostics (~$12B annual revenue). Medicare Part B lab test payments represent an estimated 10-12% of that segment. PAMA cuts have driven a ~10% cumulative reduction in Medicare Part B lab fee rates since 2018. Stabilizing the data collection method directly de-risks the primary structural headwind on LH's top line.
What the bill does
Replaces CMS-administered PAMA data collection with an independent nonprofit comprehensive claims database for setting Medicare Part B lab test payment rates, starting with data collection periods on or after January 1, 2027.
Who must act
Clinical diagnostic laboratories that bill Medicare Part B, including Quest Diagnostics.
What happens
Shifts the data source used to calculate private payor-based fee schedule rates from a CMS-mandated reporting system (which has led to steep, unpredictable rate cuts) to a qualified independent nonprofit database. This reduces the risk of CMS-administrative errors and data-weighting imbalances that have caused 10-15% cumulative PAMA cuts since 2018.
Stock impact
DGX's largest revenue segment is Diagnostic Information Services (~$10B annual revenue). Medicare Part B lab test payments represent an estimated 10-12% of that segment. PAMA cuts have driven a ~15% cumulative reduction in effective Medicare rates since 2018. Stabilizing the data collection method directly de-risks the primary structural headwind on DGX's top line.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
CHOICE for Veterans Act of 2025
ASAP Act
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Thyroid Disease CARE Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.